Guardant Health: FDA Approval, Quest Partnership, and Stock Volatility
Update: 2025-09-29
Description
Guardant Health stock jumps after FDA approves its Guardant360 blood test to identify breast cancer patients who may benefit from Eli Lilly's new treatment. This marks the sixth FDA clearance for Guardant360 as a companion diagnostic and the second in breast cancer. A new partnership with Quest Diagnostics expands access to Guardant's Shield colorectal cancer test. Wells Fargo initiated coverage with an overweight rating, while the stock, up 93% over the past year, remains volatile despite recent gains and a confident financial outlook.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
